探索新的前沿:利用STAT3信号进行先进的癌症治疗
Taiwo Adesoye1, Debasish Tripathy2, Kelly K Hunt1
1Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers
|February 10, 2024
概括
信号转换器和转录激活器3 (STAT3) 对于细胞功能至关重要,但其失调会导致癌症. 本综述探讨了STAT3机制,它在癌症中的作用,以及针对STAT3进行临床应用的新型治疗策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 信号转换器和转录3激活器 (STAT3) 是一个关键的转录因子,调节细胞增殖,分化,血管生成和存活.
- STAT3激活涉及由上游激酶启动的复杂酸化事件,严格控制下游基因表达.
- 异常的STAT3激活与各种癌症的发展和进展有关,包括瘤发生,转移和复发.
研究的目的:
- 审查STAT3激活的复杂机制及其在生理和恶性背景下的下游影响.
- 概述目前和新兴的治疗策略,旨在针对癌症治疗的STAT3.
- 总结新型STAT3向药物的临床前和临床证据,并讨论其临床实施的挑战.
主要方法:
- 关于STAT3信号通路的文献综述.
- 分析STAT3在正常细胞过程和癌症发展中的作用.
- 对STAT3抑制剂的临床前和临床研究数据的综合.
主要成果:
- 详细介绍了STAT3在正常生理学和癌症发病过程中的双重作用.
- 确定了STAT3的各种上游激活器和下游目标.
- 提出了新型STAT3向药物的疗效和局限性的证据.
结论:
- STAT3是细胞过程中的关键调解者,也是癌症的重要驱动因素.
- 准STAT3为多种癌症提供了一个有希望的治疗途径.
- 需要进一步的研究和临床开发来克服挑战,并确定STAT3抑制剂的治疗疗效.
更多相关视频
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


